10/23/2026 14:15
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer

New data from HERIZON-GEA-01 Phase 3 trial show 36-month overall survival of nearly 40% with TEVIMBRA plus ZIIHERA and chemotherapy, and median OS reaching 27 months TEVIMBRA-containing arm was associated with a four-month longer median OS compared with ZIIHERA plus chemotherapy BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZO...

10/23/2026 14:10
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project

Lifezone Metals Limited ( NYSE: LZM ) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Pr...

New Galderma Research Reveals More Than Half of Women Mistake Menopause-Related Skin Changes for Signs of Ageing

Galderma (SIX: GALD) today announced new global research revealing that more than half (56%) of women first put menopause-related skin changes down to general ageing, while only less than a third of women (29%) initially recognized the link to menopause.1The research shines a light on‘The Menopausal Skin Misread’, showing how aesthetic changes in the skin linked to menopause are still being misunderstood, mislabeled and too often attributed to ageing alone.1Ahead of World Menopause Day, Galderma is calling attention to the misunderstood impact of menopause on the skin, helping to close...
Anglais
Subscribe to